Literature DB >> 17873677

Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.

Dolly A Parasrampuria1, Kerri A Schoedel, Reinhard Schuller, Steven A Silber, Patrick E Ciccone, Joan Gu, Edward M Sellers.   

Abstract

The primary objective of this study was to determine if the abuse liability of methylphenidate is governed by formulation differences that affect rates of drug delivery. In this double-blind, placebo-controlled, randomized, crossover study, subjects with a history of recreational drug use received single oral doses of placebo, 60 mg of immediate-release methylphenidate (IR) and 108 mg of extended-release methylphenidate (osmotic release oral system [OROS]). Over 24 hours after dosing, blood was collected to determine plasma concentrations of methylphenidate, and subjects completed subjective assessments of abuse liability (Addiction Research Center Inventory, Drug Rating Questionnaire-Subject, and Subjective Drug Value). The abuse-related subjective effects of IR and OROS methylphenidate were statistically significantly different from placebo, confirming the overall validity of the study. Although a higher dose of OROS methylphenidate was used compared with IR methylphenidate (108 mg vs 60 mg), subjective effects were consistently lower for OROS compared with IR methylphenidate (statistically significant for 3 of 6 measures of positive effects), particularly at early time points. In general, pharmacokinetic-pharmacodynamic parameters were correlated from a poor to modest degree, with greater correlations observed for IR methylphenidate. In addition, a post hoc "qualification" method was developed, which demonstrated that pharmacological qualification might improve the assessment of subjective effects. Although requiring epidemiological confirmation, the results suggest that OROS methylphenidate, with its characteristic slow ascending plasma concentration profile, may have lower abuse potential. This conclusion is reflected by lower subjective responses during early hours as compared with the IR formulation with its rapid drug delivery and accompanying greater subjective effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873677     DOI: 10.1097/jcp.0b013e3181515205

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  27 in total

Review 1.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

2.  Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder.

Authors:  M Feldman; S Bélanger
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

3.  Oral methylphenidate establishes a conditioned place preference in rats.

Authors:  Thomas E Wooters; Matthew T Walton; Michael T Bardo
Journal:  Neurosci Lett       Date:  2010-10-23       Impact factor: 3.046

Review 4.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

Review 5.  Abuse-deterrent opioid formulations: are they a pipe dream?

Authors:  Nathaniel Katz
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

6.  Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.

Authors:  Liang Li; Yaning Wang; Ramana S Uppoor; Mehul U Mehta; Tiffany Farchione; Mitchell V Mathis; Hao Zhu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-18       Impact factor: 2.745

7.  Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?

Authors:  Laura Brandt; Thomas Chao; Sandra D Comer; Frances R Levin
Journal:  Addiction       Date:  2020-09-28       Impact factor: 6.526

Review 8.  Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.

Authors:  Marit D Moen; Susan J Keam
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

9.  Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial.

Authors:  Marc E Mooney; David V Herin; Joy M Schmitz; Nidal Moukaddam; Charles E Green; John Grabowski
Journal:  Drug Alcohol Depend       Date:  2008-12-05       Impact factor: 4.492

Review 10.  Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Authors:  José Pérez de los Cobos; Núria Siñol; Víctor Pérez; Joan Trujols
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.